RESEARCH TRIANGLE PARK, N.C. – June 15, 2015 – Quintiles, the world’s largest biopharmaceutical services company, today announced the addition of advanced statistical monitoring and predictive analytics capabilities to its risk-based monitoring (RBM) solution. Predictive and Advanced Analytics combine Quintiles’ experience as the RBM leader with its deep therapeutic and strong statistical sciences heritage to enable study teams to identify the right signals and predict clinical trial site performance and potential patient safety issues.
Predictive and Advanced Analytics are the first such model-based capabilities fully integrated into an RBM solution on the market today. Underpinned by the award-winning Quintiles Infosario® technology platform and Quintiles’ deep data resources, these new capabilities improve precision in risk identification by better understanding underlying “white noise” from safety trigger processes.
“The ultimate goal of risk-based monitoring is to increase the efficiency of drug development while improving quality and patient safety,” said Margaret Keegan, senior vice president, Data Sciences & Strategy at Quintiles. “The ability to cut through all the noise and predict potential risks before they occur means we can target the right action at the right place at the right time. It is a major step forward in improving quality and productivity in the next generation of RBM execution.”
Quintiles is the RBM market leader currently engaged in more than 130 studies using RBM processes and policies, across more than 26,000 sites and 260,000 patients. Compliant with U.S. Food and Drug Association, European Medicines Agency and TransCelerate guidance, Predictive and Advanced Analytics use unique statistical algorithms specifically designed for optimal RBM execution. The capabilities combine inputs across multiple variables including operational performance and study data to provide unprecedented insights into potential study risks.
“Being able to target patients and sites with this level of accuracy takes RBM to a new level in terms of both speed and quality,” said Teresa Lamantia, senior vice president, Knowledge Management at Quintiles. “The ability to focus resources where they’re needed to protect patient safety and the integrity of the trial is a welcome advance for all of us working to transform clinical development.”
Quintiles’ experts will be available to discuss RBM and the new Predictive and Advanced Analytics functionality at its booth at the upcoming Drug Information Association (DIA) conference June 14-18, 2015, in Washington, D.C. In addition, a discussion of Predictive and Advanced Analytics will be included in a Quintiles presentation at 12 p.m. EDT, June 16 at DIA’s Innovation Theater. For more information about Quintiles’ Predictive and Advanced Analytics capabilities, visit the Quintiles booth at DIA (#601) or watch this video: www.quintiles.com/library/videos/predictive-and-advanced-analytics.
Quintiles (NYSE: Q) helps biopharma and other healthcare companies improve their probability of success by connecting insights from our deep scientific, therapeutic and analytics expertise with superior delivery for better outcomes. From advisory through operations, Quintiles is the world’s largest provider of product development and integrated healthcare services, including commercial and observational solutions. Conducting operations in approximately 100 countries, Quintiles is a member of the FORTUNE 500 and has been named to FORTUNE’s list of the “World’s Most Admired Companies.” To learn more, visit www.quintiles.com.
Mari Mansfield, Media Relations (firstname.lastname@example.org)
+ 1.919.998.2639 (office) +1.919.259.3298 (mobile)
Todd Kasper, Investor Relations (InvestorRelations@quintiles.com)